Trial0

Clinical trial · NCT07307664 · RECRUITING · NA

Increasing Germline Genetic Testing for Patients With Cancer

Sponsor: Josh Peterson

We save this real registry record and notify you if its published status changes. Create an account to add profile details that improve future matching.

Summary

Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite of implementation strategies to increase germline test ordering by oncology care teams (i.e., mainstreaming) for eligible patients with breast, pancreatic or colorectal cancer. Secondarily, the study will investigate completion of testing by eligible patients, as well as impact on overall rates of germline test ordering in patients with cancer. The network will bundle and deploy different implementation strategies across the clinical sites in three 6-month phases. A maintenance phase after the implementation periods will measure genetic testing rates without any additional implementation strategies to determine persistence of effects. The implementation strategies address clinician-level factors, and thus oncologists and their team members (e.g. advanced practice providers, nurse navigators, case managers) will be the focus of evaluating the impact of implementation strategies. Strategies that will be considered include provider education, audit and feedback reports, facilitation, peer support, and electronic health record (EHR) system optimization to support germline testing. Using the RE-AIM QuEST framework, outcomes will be assessed using mixed methods separately for each eligible cancer type. Data collection from the EHR, other relevant data sources, and qualitative provider feedback will be used to assess ordering and completion of tests and the effect of the implementation strategies on germline testing rates in oncology clinics.

Interventions

  • Implementation strategies · BEHAVIORAL

    We will deploy different strategy bundles across the clinical sites in three approximate 6-month phases. Phase I - Facilitation of provider training, educational materials, and information resources; Patient-facing educational material and information resources Phase II - Audit and feedback report on existing patients; Practice champion support; Optimizing EHR strategies Phase III - EHR tools to facilitate prospective identification of patients, testing, and result reporting

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Oncology care team members (including, but not limited to, oncologists, advanced practice providers, nurse navigators, caring for patients with adult patients with breast cancer, pancreatic cancer or colorectal cancer.

Exclusion Criteria:

* Providers not on the oncology care team

Sites (10)

  • VA Greater Los Angeles Healthcare System, Los Angeles, California · RECRUITING
  • Orlando VA Medical Center, Orlando, Florida · RECRUITING
  • Atlanta VA Medical Center, Decatur, Georgia · RECRUITING
  • Northwestern Medicine, Chicago, Illinois · RECRUITING
  • Indiana University School of Medicine, Indianapolis, Indiana · RECRUITING
  • Durham VA Medical Center, Durham, North Carolina · RECRUITING
  • Salisbury VA Health Care System, Salisbury, North Carolina · RECRUITING
  • Geisinger, Danville, Pennsylvania · RECRUITING
  • Vanderbilt University Medical Center, Nashville, Tennessee · RECRUITING
  • University of Utah Health, Salt Lake City, Utah · RECRUITING

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2026-06-09.